Medicare

Family Medicine Specialists Selects Cardio Diagnostics’ Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists...

Model N Responds to Mounting Regulatory Pharma Pressures with Innovations that Ensure Compliance and Optimize Revenue

340B, Inflation Reduction Act, and global pricing innovations help leading life sciences companies manage regulatory, compliance, and discounting challengesSAN MATEO,...

Simple HealthKit Partners with Imperial Health Plan of California, Inc. to Provide Comprehensive At-Home Diagnostics Programs to Medicare Advantage Members

Imperial Health selected Simple HealthKit for its ability to deliver high-quality tests, real-time data analytics and a great member experience,...

Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation activation company focused on the discovery,...

Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two...

error: Content is protected !!